10.91
前日終値:
$10.97
開ける:
$11.06
24時間の取引高:
856.24K
Relative Volume:
0.79
時価総額:
$551.21M
収益:
-
当期純損益:
$-156.39M
株価収益率:
-2.9566
EPS:
-3.69
ネットキャッシュフロー:
$-123.06M
1週間 パフォーマンス:
-1.98%
1か月 パフォーマンス:
-10.43%
6か月 パフォーマンス:
-20.77%
1年 パフォーマンス:
+6.23%
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
名前
Kalvista Pharmaceuticals Inc
セクター
電話
(857) 999-0075
住所
200 CROSSING BOULEVARD, FRAMINGHAM, MA
KALV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
KALV
Kalvista Pharmaceuticals Inc
|
10.91 | 554.24M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-31 | 開始されました | JMP Securities | Mkt Outperform |
| 2025-01-07 | 開始されました | TD Cowen | Buy |
| 2024-12-18 | 開始されました | BofA Securities | Buy |
| 2020-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2019-07-29 | 開始されました | SVB Leerink | Outperform |
| 2019-03-20 | 開始されました | Needham | Buy |
| 2018-10-30 | 開始されました | Jefferies | Buy |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-08-31 | 開始されました | BTIG Research | Buy |
すべてを表示
Kalvista Pharmaceuticals Inc (KALV) 最新ニュース
Will KalVista Pharmaceuticals Inc. stock attract more institutional investorsMarket Trend Summary & Daily Stock Trend Reports - newser.com
How KalVista Pharmaceuticals Inc. stock performs in high volatility marketsJuly 2025 Review & Risk Controlled Stock Alerts - newser.com
Will KalVista Pharmaceuticals Inc. stock reach Wall Street targets2025 Bull vs Bear & Precise Swing Trade Entry Alerts - newser.com
What makes KalVista Pharmaceuticals Inc. stock attractive to growth funds2025 Price Momentum & Smart Money Movement Tracker - newser.com
Exit strategy if you’re trapped in KalVista Pharmaceuticals Inc.July 2025 Big Picture & Safe Entry Momentum Tips - newser.com
Multi asset correlation models including KalVista Pharmaceuticals Inc.Portfolio Gains Summary & Safe Capital Growth Trade Ideas - newser.com
Using R and stats models for KalVista Pharmaceuticals Inc. forecasting2025 Institutional Moves & Community Verified Swing Trade Signals - newser.com
Will a bounce in KalVista Pharmaceuticals Inc. offer an exit2025 Support & Resistance & Daily Oversold Bounce Ideas - newser.com
How hedge fund analytics apply to KalVista Pharmaceuticals Inc. stockM&A Rumor & AI Driven Price Forecasts - newser.com
Can KalVista Pharmaceuticals Inc. (4XC1) stock sustain margin levelsInsider Buying & Technical Entry and Exit Tips - newser.com
Is KalVista Pharmaceuticals Inc. (4XC1) stock a defensive play amid uncertaintyJuly 2025 Review & Technical Buy Zone Confirmation - newser.com
Will KalVista Pharmaceuticals Inc. (4XC1) stock keep high P E multiplesJuly 2025 Catalysts & Safe Entry Momentum Stock Tips - newser.com
Will KalVista Pharmaceuticals Inc. (4XC1) stock benefit from commodity supercycleJuly 2025 Market Mood & Verified Technical Trade Signals - newser.com
KalVista, Ionis/Sobi among latest to win EU nod for rare disease drugs - MSN
How to track smart money flows in KalVista Pharmaceuticals Inc.Weekly Trend Report & Weekly Top Gainers Alerts - newser.com
Emerald Mutual Fund Advisers Trust Increases Stake in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Why KalVista Pharmaceuticals Inc. (4XC1) stock is favored by hedge fundsJuly 2025 EndofMonth & Accurate Entry and Exit Point Alerts - newser.com
How strong is KalVista Pharmaceuticals Inc. (4XC1) stock earnings growthJuly 2025 Trends & Target Return Focused Stock Picks - newser.com
What market sentiment indicators show for KalVista Pharmaceuticals Inc. (4XC1) stock2025 Institutional Moves & Consistent Growth Stock Picks - newser.com
Emerald Advisers LLC Boosts Stock Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Pass Below Fifty Day Moving AverageWhat's Next? - MarketBeat
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting - The Joplin Globe
KalVista’s Icatibant Study: A Potential Game-Changer for HAE Treatment? - MSN
Kalvista Pharmaceuticals Inc (KALV) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):